Monday, June 17, 2019

Soliton Takes $9.45M In Private Placement

Houston-based Soliton, a publicly traded developer of medical device technology licensed from the University of Texas, said today that it has raised $9.45M in a private placement. The company--which trades as SOLY on the NASDAQ--said the funding was led by Remeditex Ventures, the company's largest shareholder. Remeditex took $5.0 of the private placement. Soliton's technology is licensed from The University of Texas on behalf of the MD Anderson Cancer Center. The company said the proceeds will go towards working capital.